Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy. The therapy is designed to overcome key barriers that have limited the success of cellular therapies in solid tumours. … Read More
A new agreement is set to advance a vaccine for ovarian cancer which has shown 40% cancer-free survival rates. Biotechnology company CellxLife has entered an agreement with Mayo Clinic for the dendritic cell vaccine, which reported the 40% 10-year cancer-free survival rate in a Phase I Mayo Clinic study… Read More
DDW Editor Reece Armstrong speaks to Jeff Glazier, CEO of General Oncology, about the challenges facing pancreatic cancer drug development and… Read More
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a clinical trial application for a therapy targeting advanced high-grade serous ovarian cancer. CryptiVax-1001, developed by biotechnology company Epitopea, is an off-the-shelf mRNA therapeutic vaccine. It is designed to drive targeted immune responses using a set of tumour-specific antigens… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, key breakthroughs emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical… Read More
News round-up for 13 – 17 April by Bruno Quinney, Content Team at DDW. This week, breakthroughs have emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical trial set up in the UK. The top stories: Novel therapy could slow tumour growth… Read More
Corcept Therapeutics has shared final overall survival data from its pivotal Phase III ROSELLA trial of Lifyorli (relacorilant) combined with the chemotherapeutic agent nab-paclitaxel in patients with platinum-resistant ovarian cancer. The results were shared in a late-breaking oral presentation at the Society of Gynecologic Oncology (SGO) 2026… Read More
The global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (Mo-Rez) has shown confirmed objective response rates (cORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent or advanced endometrial cancer (EC). Mocertatug rezetecan is a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. B7-H4… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More
The US Food and Drug Administration (FDA) has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is approved in patients who have received one to three prior systemic treatment regimens, at least… Read More
Biotechnology firm Theolytics has been awarded €8 million research funding through the Horizon Europe programme, to support expansion of the OCTOPOD‑IV Phase IIa trial in platinum‑resistant ovarian cancer. The trial will evaluate THEO‑260 — a next‑generation oncolytic immunotherapy designed… Read More
The European Innovation Council (EIC) has awarded €2.5 million to biotechnology company Step Pharma to accelerate the development of dencatistat for CTPS2 null gynaecological tumours. The funding, which consists of a €2.5 million grant and potentially up to €10 million in equity investment, is part of the EIC’s Accelerator Award,… Read More
A new treatment for ovarian cancer could prevent peritoneal recurrence, data suggests. Biotech company Oncoinvent is set to present results from the Phase I study of Radspherin after cytoreductive surgery in patients with platinums ensitivesensitive epithelial ovarian cancer. According to data released in advance, nine of 10 patients treated on the highest dose remained free… Read More
Corcept Therapeutics has announced that ROSELLA, the company’s Phase III trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint. In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 35% reduction in the risk of… Read More
News round-up for 12 – 16 January by Bruno Quinney, Content Team at DDW. This week in DDW, new research in women’s health has uncovered significant findings related to endometriosis and ovarian cancer. Elsewhere, can ageing be reversed? The top stories: Discovery reveals endometriosis is not… Read More
A novel DNA-based therapy could increase survival rates for women with platinum-resistant ovarian cancer, a new paper reveals. A new clinical study, published in the International Journal of Gynecological Cancer, shows the DNA-based therapy Elenagen, when administered in combination with standard chemotherapy drug gemcitabine, significantly extended overall survival… Read More
